Polymorphisms in the and genes of the SUMO-conjugating system and breast cancer risk

Thomas Dünnebier (1) , Justo Lorenzo Bermejo (2) , Susanne Haas (3) , Hans-Peter Fischer (3) , Christiane B. Pierl (4) , Christina Justenhoven (5, 6) , Hiltrud Brauch (5, 6) , Christian Baisch (7) , Michael Gilbert (1) , Volker Harth (4, 7) , Anne Spickenheuer (4) , Sylvia Rabstein (4) , Beate Pesch (4) , Thomas Brüning (4) , Yon-Dschun Ko (7) , Ute Hamann (1)

1 Molecular Genetics of Breast Cancer (B055)
2 Institute of Medical Biometry and Informatics
3 Institute of Pathology
4 BGFA-Forschungsinstitut für Arbeitsmedizin der Deutschen Gesetzlichen Unfallversicherung
5 Dr. Margarete Fischer-Bosch Institute for Clinical Pharmacology [Stuttgart]
6 Eberhard Karls Universität Tübingen = Eberhard Karls University of Tuebingen
7 Department of Internal Medicine

SUMOylation consists in the covalent conjugation of small ubiquitin-related modifiers to target proteins. SUMOylation participates in processes that are tightly linked to tumorigenesis, and genetic variability in the SUMO-conjugating system may influence the development of breast cancer. We recently reported that variation in the gene encoding the SUMO-conjugating enzyme may affect the grade of breast tumors. Following comprehensive analyses for detection of putative functional polymorphisms in 14 genes of the SUMO system, we selected one coding SNP in and seven tag SNPs in for association analyses. Results were based on 1,021 cases, and 1,015 matched controls from the population-based GENICA study. Odds ratios (OR) and 95% confidence intervals (CI) were estimated by conditional logistic regression. To explore the association with polymorphisms closely linked to the genotyped variants, multiple imputation based on HapMap data was applied. The study revealed associations of four polymorphisms with risk of grade 1 tumors. Comparison of genotype and haplotype models indicated that the best representation of risk solely relied on rs7187167 under dominant penetrance. Women carrying the rare allele showed an increased risk of grade 1 tumors compared with common homozygotes (OR 1.87, 95% CI 1.18–2.95). This effect appeared to be stronger in women with a family history of breast or ovarian cancer. Imputation of polymorphisms in a 300-kb region around the genotyped polymorphisms identified no variants with stronger associations. Our findings suggest that genetic variation in may affect the risk of grade 1 breast tumors.

Mots clés: and polymorphisms; SUMOylation; Breast cancer risk; Tumor grade; Multiple imputation

Thomas Dünnebier, Justo Lorenzo Bermejo, Susanne Haas, Hans-Peter Fischer, Christiane B. Pierl, et al.. Polymorphisms in the and genes of the SUMO-conjugating system and breast cancer risk. Breast Cancer Research and Treatment, 2009, 121 (1), pp.185-194. ⟨10.1007/s10549-009-0530-y⟩. ⟨hal-00485068⟩